PharmaCyte Biotech Inc
PMCB
Market Cap$13.59M
Close$
$5.24
394.1% upside
Current Fair Value
394.1% upsideUndervalued by 394.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.59 Million |
|---|---|
| Enterprise Value | $-2,427,761.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.8 |
| Beta | -0.21 |
| Outstanding Shares | 7,866,387 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.52 |
|---|---|
| PEG | 0.13 |
| Price to Sales | - |
| Price to Book Ratio | 0.21 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.54 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -0.15 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About PharmaCyte Biotech Inc
4 employeesPharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." This technology is being use...